Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 5/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485638 | 1.00 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2485634 | 1.00 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2488014 | 0.89 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2488012 | 0.89 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2491776 | 0.89 | GPR119 (0.46) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2488013 | 0.89 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL3743598 | 0.89 | GPR119 (0.46) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2491778 | 0.89 | GPR119 (0.46) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL3743594 | 0.89 | GPR119 (0.46) | GSK3BCYP1A2CYP2D6LATS1LATS2 | |
| SCHEMBL2490501 | 0.88 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6LATS1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2057141-B1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PROD INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | PFIZER INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292205-A1 | Pyrimidone Compounds As GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CYP1A2 1200/4885CYP2D6 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.